Table 1 Patient characteristics for the Holland study and the pooled data (including the Holland and Australian study)
Holland study | Pooled data (Holland + Australia) | |||||
|---|---|---|---|---|---|---|
All (N = 20) | Active (N = 10) | Sham (N = 10) | All (N = 40) | Active (N = 20) | Sham (N = 20) | |
Age, years | 69.0 ± 8.5 | 72.2 ± 6.1 | 65.7 ± 9.6 | 63.4 ± 14 | 64.5 ± 14.9 | 62.4 ± 13.3 |
Sex, male/female | 14/6 | 8/2 | 6/4 | 26/14 | 15/5 | 11/9 |
Body mass index, kg/m2 | 26.4 ± 4.4 | 25.9 ± 5.1 | 26.8 ± 3.8 | 26.4 ± 4.4 | 26.8 ± 4.5 | 26.5 ± 3.2 |
History of COPD, % (n/N) | 50 (10/20) | 60 (6/10) | 40 (4/10) | 25 (10/40) | 30 (6/20) | 20 (4/20) |
MV duration at enrollment, days | 2.5 ± 1.0 | 2.4 ± 1.0 | 2.5 ± 1.0 | 2.5 ± 0.8 | 2.5 ± 0.9 | 2.5 ± 0.8 |
FiO2 at study enrollment | 0.42 ± 0.12 | 0.42 ± 0.09 | 0.42 ± 0.15 | 0.36 ± 0.13 | 0.34 ± 0.11 | 0.37 ± 0.15 |
Primary reason for MV, % (n/N) | ||||||
Cardiac arrest | 5 (1/20) | 0 (0/0) | 10 (1/10) | 2.5 (1/40) | 0 (0/20) | 5 (1/20) |
Pneumonia | 50 (10/20) | 40 (4/10) | 60 (6/10) | 30 (12/40) | 25 (5/20) | 35 (7/20) |
Postoperative | 5 (1/20) | 10 (1/10) | 0 (0/0) | 5 (2/40) | 10 (2/20) | 0 (0/20) |
Exacerbation COPD | 25 (5/20) | 30 (3/10) | 20 (2/10) | 12.5 (5/40) | 15 (3/20) | 10 (2/20) |
Neurologic dysfunction | 10 (2/20) | 10 (1/10) | 10 (1/10) | 32.5 (13/40) | 40 (8/20) | 25 (5/20) |
Sepsis | 0 (0/0) | 0 (0/0) | 0 (0/0) | 12.5 (5/40) | 5 (1/20) | 20 (4/20) |
Other | 5 (1/20) | 10 (1/10) | 0 (0/0) | 2.5 (2/40) | 5 (1/20) | 5 (1/20) |
Successfully extubated during study, % (n/N) | 60 (12/20) | 80 (8/10) | 40 (4/10) | 65 (26/40) | 80 (16/20) | 50 (10/20) |